View all Podcasts
Health FDA Reform, Pharmaceuticals
June 10th, 2010 Podcast

Tom Philipson and Eric Sun discuss their new report "Cost of Caution: The Impact on Patients of delayed drug approvals," and how to save lives by streamlining the FDA's drug-development process

Table of Contents

Tom Philipson and Eric Sun discuss their new report "Cost of Caution: The Impact on Patients of delayed drug approvals," and how to save lives by streamlining the FDA's drug-development process.

Previous Episodes

- - -
-
-

-

- - -
-
-

-

- - -
-
-

-